Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma

Medicine (United States)

Volumn 93, Issue 27, 2014, Pages

  Vavallo, Antonio ^a   Simone, Simona ^c   Lucarelli, Giuseppe ^a   Rutigliano, Monica ^a   Galleggiante, Vanessa ^a   Grandaliano, Giuseppe ^b   Gesualdo, Loreto ^d   Campagna, Marcello ^a   Cariello, Marica ^c   Ranieri, Elena ^b   Pertosa, Giovanni ^c   Lastilla, Gaetano ^a   Selvaggi, Francesco Paolo ^a   Ditonno, Pasquale ^a   Battaglia, Michele ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c Dialysis and Transplantation Unit   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY CARCINOMA; KIDNEY FUNCTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TUMOR VOLUME; AGED; COMPLICATION; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; ITALY; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; RISK FACTOR;

AGED; CARCINOMA, RENAL CELL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84919330746     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000183     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
2. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009; 16: 1103-1123.
3. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidem. 2004; 159: 1160-1167.
4. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus. a systematic review and meta-analysis. JAMA. 2008; 300: 2754-2764.
5. Magliano DJ, Davis WA, Shaw JE, et al. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol. 2012; 167: 589-599.
6. Emerging Risk Factors CollaborationSeshasai SR, Kaptoge S, Thompson A, et al. . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364: 829-841.
7. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
8. Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol. 2008; 179: 2096-2102.
9. Lucarelli G, Ditonno P, Bettocchi C, et al. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers. 2014689795. doi: 10.1155/2014/689795.
10. Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia. 2011; 4: 1013-1018.
11. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92: 2076-2083.
12. Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006; 49: 2819-2823.
13. Yang WS, Va P, Bray F, et al. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One. 2011; 6: e27326doi: 10.1371/journal.pone.0027326.
14. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012; 130: 1639-1648.
15. Lindblad P, Chow WH, Chang J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia. 1999; 42: 107-112.
16. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997; 89: 1360-1365.
17. Lindblad P, Adami HO. Kidney cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Textbook of Cancer Epidemiology. New York: Oxford University Press; 2012: 467-485.
18. Ha YS, Kim WT, Yun SJ, et al. Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann Surg Oncol. 2013; 20: 3662-3668.
19. Fukushima H, Masuda H, Yokoyama M, et al. Diabetes mellitus with obesity is a predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Jpn J Clin Oncol. 2013; 43: 740-746.
20. Hofner T, Zeier M, Hatiboglu G, et al. The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World J Urol. 2013doi: 10.1007/s00345-013-1231-z [Epub ahead of print].
21. Antonelli A, Arrighi N, Corti S, et al. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study. Urol Oncol. 2013; 31: 1310-1315.
22. Süer E, Oztürk E, Gülpinar O, et al. Effect of type 2 diabetes mellitus on prognosis of non-metastatic renal cell cancer. Korean J Urol. 2013; 54: 499-503.
23. Psutka SP, Stewart SB, Boorjian SA, et al. Diabetes mellitus is independently associated with an increased risk of mortality among clear cell renal cell carcinoma patients. J Urol. 2014pii: S0022- 534703764-1. doi: 10.1016/j.juro.2014.06.014 [Epub ahead of print].
24. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685.
25. Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and Cancer project (Me-Can): analysis of six prospective cohorts. PLoS Med. 2009; 6: e1000201.
26. Parr CL, Batty GD, Lam TH, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424, 519 participants. Lancet Oncol. 2010; 11: 741-752.
27. Atchison EA, Gridley G, Carreon JD, et al. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011; 128: 645-653.
28. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7, 12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 1972; 32: 226-232.
29. Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990; 86: 1503-1510.
30. Simone S, Gorin Y, Velagapudi C, et al. Mechanism of oxidative DNA damage in diabetes: tuberin inactivation and downregulation of DNA repair enzyme 8-oxo-7, 8-dihydro-2-deoxyguanosine-DNA glycosylase. Diabetes. 2008; 57: 2626-2636.
31. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2: 48-53.